 | • レポートコード：MRC2303F0151 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、231ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：獣医 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料は、2021年に7,871.88百万ドルであった世界の獣医/動物用ワクチン市場規模が、2022年に8,396.54百万ドルになり、2027年まで年平均6.84%で成長して11,709.34百万ドルに到達すると予想しています。本調査資料では、獣医/動物用ワクチンの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（水産養殖ワクチン、コンパニオンアニマルワクチン、家畜ワクチン、豚ワクチン、家禽ワクチン）分析、疾患別（水産養殖、コンパニオンアニマル、家畜、豚、家禽）分析、技術別（不活性化ワクチン、弱毒生ワクチン、組換えワクチン、トキソイドワクチン）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。さらに、市場参入企業として、Aptimmune Biologics, Inc.、Biogenesis Bago、Boehringer Ingelheim Vetmedica, Inc.、Brilliant Bio Pharma Private Limited、Ceva Santé Animale、China Animal Husbandry Industry Co., Ltd、Elanco Animal Health Incorporated、Endovac Animal Health、Heska Corp.、Hester Biosciences、Hipra、IDT Biologika GmbH、Indian Immunological Limited、Inner Mongolia Jinyu Group Co Ltdなどの情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の獣医/動物用ワクチン市場規模：種類別 - 水産養殖ワクチンの市場規模 - コンパニオンアニマルワクチンの市場規模 - 家畜ワクチンの市場規模 - 豚ワクチの市場規模 - 家禽ワクチンの市場規模 ・世界の獣医/動物用ワクチン市場規模：疾患別 - 水産養殖疾患における市場規模 - コンパニオンアニマル疾患における市場規模 - 家畜疾患における市場規模 - 豚疾患における市場規模 - 家禽疾患における市場規模 ・世界の獣医/動物用ワクチン市場規模：技術別 - 不活性化ワクチンの市場規模 - 弱毒生ワクチンの市場規模 - 組換えワクチンの市場規模 - トキソイドワクチンの市場規模 ・世界の獣医/動物用ワクチン市場規模：地域別 - 南北アメリカの獣医/動物用ワクチン市場規模 アメリカの獣医/動物用ワクチン市場規模 カナダの獣医/動物用ワクチン市場規模 ブラジルの獣医/動物用ワクチン市場規模 ... - アジア太平洋の獣医/動物用ワクチン市場規模 日本の獣医/動物用ワクチン市場規模 中国の獣医/動物用ワクチン市場規模 インドの獣医/動物用ワクチン市場規模 韓国の獣医/動物用ワクチン市場規模 台湾の獣医/動物用ワクチン市場規模 ... -ヨーロッパ/中東/アフリカの獣医/動物用ワクチン市場規模 イギリスの獣医/動物用ワクチン市場規模 ドイツの獣医/動物用ワクチン市場規模 フランスの獣医/動物用ワクチン市場規模 ロシアの獣医/動物用ワクチン市場規模 ... -その他地域の獣医/動物用ワクチン市場規模 ・競争状況 ・企業情報 |
The Global Veterinary/Animal Vaccines Market size was estimated at USD 7,871.88 million in 2021 and expected to reach USD 8,396.54 million in 2022, and is projected to grow at a CAGR 6.84% to reach USD 11,709.34 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Veterinary/Animal Vaccines to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Aquaculture Vaccine, Companion Animal Vaccine, Livestock Vaccine, Porcine Vaccine, and Poultry Vaccine.
Based on Disease, the market was studied across Aquaculture, Companion Animal, Livestock, Porcine, and Poultry.
Based on Technology, the market was studied across Inactivated Vaccine, Live Attenuated Vaccine, Recombinant Vaccine, and Toxoid Vaccine.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Veterinary/Animal Vaccines market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Veterinary/Animal Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Veterinary/Animal Vaccines Market, including Aptimmune Biologics, Inc., Biogenesis Bago, Boehringer Ingelheim Vetmedica, Inc., Brilliant Bio Pharma Private Limited, Ceva Santé Animale, China Animal Husbandry Industry Co., Ltd, Elanco Animal Health Incorporated, Endovac Animal Health, Heska Corp., Hester Biosciences, Hipra, IDT Biologika GmbH, Indian Immunological Limited, Inner Mongolia Jinyu Group Co Ltd, Merck & Co. Inc., MSD & Co. Inc, Philbro Animal Health, Ringpu(Tianjin)Bio-Pharmacy Co., Ltd, Romvac Company S.A., Torigen, Vaxxinova, VEROVACCiNES GmbH, Vetoquinol S.A., Virbac S.A., and Zoetis, Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Veterinary/Animal Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Veterinary/Animal Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Veterinary/Animal Vaccines Market?
4. What is the competitive strategic window for opportunities in the Global Veterinary/Animal Vaccines Market?
5. What are the technology trends and regulatory frameworks in the Global Veterinary/Animal Vaccines Market?
6. What is the market share of the leading vendors in the Global Veterinary/Animal Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the Global Veterinary/Animal Vaccines Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of zoonotic diseases
5.1.1.2. Increasing rate of pet adoption and growing expenditure on pet treatment
5.1.1.3. Growing consumption of meat
5.1.2. Restraints
5.1.2.1. Lack of awareness about veterinary animal vaccines
5.1.3. Opportunities
5.1.3.1. Introduction of advanced veterinary vaccines owing to increasing research and development
5.1.3.2. Technological advancement enhancing the process of creating vaccines
5.1.4. Challenges
5.1.4.1. Regulations associated with the utility of vaccines
5.2. Cumulative Impact of COVID-19
6. Veterinary/Animal Vaccines Market, by Type
6.1. Introduction
6.2. Aquaculture Vaccine
6.3. Companion Animal Vaccine
6.4. Livestock Vaccine
6.5. Porcine Vaccine
6.6. Poultry Vaccine
7. Veterinary/Animal Vaccines Market, by Disease
7.1. Introduction
7.2. Aquaculture
7.3. Companion Animal
7.4. Livestock
7.5. Porcine
7.6. Poultry
8. Veterinary/Animal Vaccines Market, by Technology
8.1. Introduction
8.2. Inactivated Vaccine
8.3. Live Attenuated Vaccine
8.4. Recombinant Vaccine
8.5. Toxoid Vaccine
9. Americas Veterinary/Animal Vaccines Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Veterinary/Animal Vaccines Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Veterinary/Animal Vaccines Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Aptimmune Biologics, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Biogenesis Bago
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Boehringer Ingelheim Vetmedica, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Brilliant Bio Pharma Private Limited
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Ceva Santé Animale
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. China Animal Husbandry Industry Co., Ltd
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Elanco Animal Health Incorporated
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Endovac Animal Health
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Heska Corp.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Hester Biosciences
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Hipra
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. IDT Biologika GmbH
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Indian Immunological Limited
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Inner Mongolia Jinyu Group Co Ltd
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Merck & Co. Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. MSD & Co. Inc
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Philbro Animal Health
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Ringpu(Tianjin)Bio-Pharmacy Co., Ltd
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Romvac Company S.A.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Torigen
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Vaxxinova
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. VEROVACCiNES GmbH
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Vetoquinol S.A.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Virbac S.A.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Zoetis, Inc
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing